Articles related to DEPRESSION

FDA priority review vouchers granted to three psychedelic developers and a recent executive order may accelerate regulatory timelines for psilocybin and related compounds, with clinical availability potentially within 12 months pending positive Phase 3 data.

Consumer-facing guidance from Verywell Mind highlights how depression in adults over 60 frequently manifests as somatic complaints, cognitive changes, and social withdrawal rather than overt mood symptoms.

A J Clin Psychiatry commentary proposes a risk-benefit matrix favoring empiric catatonia treatment when diagnostic uncertainty exists, citing the syndrome’s high morbidity and the effectiveness of available interventions.

Eleven commonly prescribed medication classes have been associated with new or worsening depression symptoms, with risk varying by dose, duration, and patient population.

Algorithm-guided treatment was associated with improved remission rates in 5 of 7 randomized trials of major depressive disorder, though heterogeneity in protocols and outcome measures limited direct comparability.

“The amygdala’s response to social threat appears to feed into depressive symptoms much more strongly in young males than in young females.” — John Krystal, MD, Biological Psychiatry